We're Not Very Worried About Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Rate
Allogene Therapeutics (NASDAQ:ALLO) is managing its cash burn effectively, with a cash runway of about 3.2 years based on its last reported balance sheet from June 2026. Analysts forecast the company will reach free cash flow breakeven in approximately 3 years, suggesting it should not need to raise additional cash. The company has also reduced its cash burn by 41% over the last year, indicating prudent financial management despite not generating significant revenue yet.
At $1.55 a share, TPG funds sold Allogene Therapeutics (ALLO) stock.
TPG Funds, specifically TPG Carthage Holdings, L.P. and The Rise Fund Carthage, L.P., sold a total of 18,716,306 shares of Allogene Therapeutics (ALLO) common stock at $1.55 per share on September 28, 2026. Following this sale, TPG GP A, LLC, James G. Coulter, and Jon Winkelried reported that they no longer beneficially own any shares and have ceased to be beneficial owners of more than 5% of the company's stock. This transaction signifies a complete divestment by these reporting persons from Allogene Therapeutics.
Allogene Therapeutics (ALLO) Short Interest & Short Float | Updated Sep 2026 $ALLO
Allogene Therapeutics (ALLO) had a short interest of 59.60 million shares as of September 15, 2026, representing 19.87% of its public float, an increase of 0.82% from the previous report. The short interest ratio is 11.3 days to cover. This data indicates a significant level of bearish sentiment among investors towards ALLO.
Allogene Therapeutics Inc. (ALLO) Peer Comparison – Compare with Others
This article provides a detailed peer comparison for Allogene Therapeutics Inc. (ALLO), evaluating its financial metrics against several other biotechnology and healthcare companies. Key data points such as market cap, revenue, net profit, various ratios (P/E, P/B, RoE), and growth metrics are presented, allowing investors to assess ALLO's performance relative to its industry peers. The comparison covers income statements, liabilities, assets, cash flow, profitability, growth, valuation, solvency, and operating efficiency ratios.
Citizens reiterates Allogene stock rating on CAR T pipeline progress
Citizens has reiterated its Market Outperform rating and $6.00 price target on Allogene Therapeutics Inc. (NASDAQ:ALLO), citing the biotechnology company's progress in its CAR T pipeline. The stock is currently trading at $1.78 and is considered undervalued according to InvestingPro analysis. Allogene recently reported a successful interim futility analysis for its pivotal ALPHA3 trial and a narrower-than-expected loss for Q2 2026, alongside a $200 million public offering.
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) shares have dropped 11.1% since its last earnings report, underperforming the S&P 500. The company reported a narrower-than-expected loss of 13 cents per share in Q2 2026, with nil sales, and has extended its cash runway into 2029. Despite upward trending estimates and a Zacks Rank #3 (Hold), the stock faces questions about its ability to rebound.
Allogene at Citi summit: mrD strategy and cash runway in focus
Allogene Therapeutics (ALLO) presented its minimal residual disease (MRD) strategy and financial runway at Citi's Biopharma Back to School Summit. CEO Zach Roberts highlighted strong clinical momentum for cema-cel in lymphoma and ALLO-329 in autoimmune disease, while also emphasizing early commercial preparation. The company reported $420 million in cash, providing a runway into 2029 to cover key clinical milestones and data releases.
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
Allogene Therapeutics announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026. Mr. Parker will continue to lead the finance organization during the search for his successor. The company praised his leadership during a pivotal period and expressed confidence in Allogene's strategy and pipeline.
Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Chief Financial Officer, Effective November 6, 2026
Allogene Therapeutics, Inc. has announced that its Chief Financial Officer, Geoffrey Parker, will retire on November 6, 2026. Parker will continue to lead the finance department until his retirement date, while the company searches for his replacement.
Allogene Therapeutics CFO Geoffrey Parker to Retire
Allogene Therapeutics, Inc. announced that its Chief Financial Officer, Geoffrey Parker, will retire from his position effective November 6, 2026. Parker also serves as the Executive Vice President and Principal Financial Officer for the biotechnology company. This news was released on September 2, 2026.
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
Allogene Therapeutics announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire on November 6, 2026. Parker will continue to lead the finance organization during the search for his successor. CEO Zachary Roberts praised Parker's leadership, and Parker expressed confidence in Allogene's strategy and pipeline.
Allogene Therapeutics to present pipeline and strategy updates at fall investor conferences
Allogene Therapeutics is set to present updates on its investigational pipeline and corporate strategy at upcoming fall investor conferences. The company, a leader in cell therapy, will make webcasts of these presentations available on its website. This follows recent Q2 2026 updates highlighting progress in allogeneic cell therapy programs and a new strategy to prevent relapse in LBCL patients.
Allogene Therapeutics Announces Participation in September Investor Conference
Allogene Therapeutics, a clinical-stage biotechnology company, announced its participation in the upcoming Citi Biopharma Back to School Conference. The company will present on Wednesday, September 9, at 5:00 a.m. PT/8:00 a.m. ET, with webcasts and replays available on its investor relations website. Allogene is focused on developing allogeneic CAR T products for cancer and autoimmune diseases.
Allogene Therapeutics Announces Participation in September Investor Conference
Allogene Therapeutics, Inc. (Nasdaq: ALLO) has announced its participation in the upcoming Citi Biopharma Back to School Conference on September 9, 2026. The clinical-stage biotechnology company, focused on allogeneic CAR T products for cancer and autoimmune diseases, will present at 5:00 a.m. PT/8:00 a.m. ET. Webcasts of the presentation will be available on the company's website under the Investors tab.
Allogene Therapeutics Announces Participation in September Investor Conference
Allogene Therapeutics, Inc. announced its participation in the upcoming Citi Biopharma Back to School Conference on September 9, 2026, at 5:00 a.m. PT/8:00 a.m. ET. The clinical-stage biotechnology company, focused on developing allogeneic CAR T products for cancer and autoimmune diseases, will post any available webcasts on its investor relations website. A replay of the conference will be available for approximately 30 days following the live webcast.
Allogene Therapeutics Announces Participation in September Investor Conference
Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced its participation in the upcoming Citi Biopharma Back to School Conference on September 9, 2026. The company will present at 5:00 a.m. PT/8:00 a.m. ET, with webcasts and replays available on its investor relations website. Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic CAR T products for cancer and autoimmune disease.
Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way? (ALLO)
Allogene Therapeutics' cema-cel showed significant early biological activity in clinical trials, achieving MRD clearance in 58.3% of patients and a 97.7% median ctDNA reduction by day 45. While FDA designations like RMAT and Fast Track support its development, durable efficacy is yet to be proven. Despite risks, a speculative "Buy" rating is suggested due to a potential 61% upside to a $3.50 fair-value estimate.
Allogene (NASDAQ: ALLO) exec share sale is tax ‘sell to cover’
Allogene Therapeutics (NASDAQ: ALLO) SVP and General Counsel, Douglas Earl Martin, sold 29,697 shares of common stock at $2.12 per share on August 21, 2026. This sale was a non-discretionary "sell to cover" transaction to satisfy tax withholding obligations related to the vesting of restricted stock units. After this transaction and other adjustments, Martin directly holds 488,267 shares of Allogene common stock.
Allogene (NASDAQ: ALLO) exec plans sale of 29,697 shares
Allogene Therapeutics, Inc. officer Douglas Earl Martin has filed a notice under Rule 144 to sell up to 29,697 shares of common stock, valued at $62,957.64, through Morgan Stanley Smith Barney LLC on or after August 21, 2026. These shares are part of a restricted stock unit award, with 81,719 shares vesting on August 20, 2026, as part of the company's equity compensation plan. The filing indicates a neutral impact and sentiment for the company.
Allogene Therapeutics, Inc. SEC Filing (Aug 21, 2026)
This article reports on an SEC filing by Allogene Therapeutics, Inc. (ALLO) dated August 21, 2026. The filing, a Form S-3, became effective on August 20, 2026, at 4:00 P.M. The article also provides a brief overview of the company's recent news and SEC filings, highlighting its market performance and a recent FDA RMAT designation.
Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
This article analyzes Allogene Therapeutics (NASDAQ:ALLO) and suggests it is in a strong financial position to invest in growth. It likely reviews the company's financial health, market performance, or strategic advantages that enable such investments. The analysis indicates a positive outlook regarding the company's capacity for future development.
Citizens reiterates Allogene stock rating on trial progress
Citizens reiterated a Market Outperform rating on Allogene Therapeutics Inc. (NASDAQ:ALLO), maintaining a $6.00 price target. The firm's analysis is based on discounted EPS and revenue multiples, with the company's ALPHA3 trial on track for an interim readout in mid-2027. Allogene reported strong second-quarter 2026 earnings, surpassing analyst expectations with a narrower loss and higher revenue.
Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO
Walleye Capital LLC has invested $6.80 million in Allogene Therapeutics, acquiring 3.27 million shares, representing approximately 0.95% of the company. Other institutional investors have also adjusted their stakes, with a significant 83.63% of the stock owned by institutional investors and hedge funds. Allogene Therapeutics recently reported a smaller-than-expected quarterly loss and maintains a "Moderate Buy" consensus rating from analysts, despite a recent downgrade from Weiss Ratings.
Allogene Therapeutics (ALLO): Frazier funds disclose 5.6% ownership and affiliated stakes
Frazier Life Sciences Public Fund, L.P. has reported a 5.6% ownership stake in Allogene Therapeutics (ALLO), holding 19,445,046 shares. Other affiliated Frazier funds also hold additional stakes, bringing the total reported beneficial ownership by various Frazier entities and individuals to a significant portion of Allogene's common stock. This disclosure is made via an amended Schedule 13G filing, detailing shared voting and dispositive powers for these holdings.
Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy
The FDA has granted RMAT and Fast Track designations to Allogene's TALEN-edited, allogeneic CD19 CAR T-cell therapy, cema-cel, for first-line consolidation in large B-cell lymphoma. An interim analysis showed cema-cel cleared minimal residual disease in a significant proportion of patients, with no serious adverse events reported. These designations aim to facilitate regulatory interaction for this innovative cell therapy.
Allogene Therapeutics, Inc. Q2 2026 Earnings Call Summary
Allogene Therapeutics is strategically shifting its CAR-T platform to focus on off-the-shelf availability and community treatment, particularly for high-risk patients. The company is accelerating site activation for its ALPHA3 program and is on track for key clinical updates and regulatory milestones for Cema-Cel and ALLO-329, despite acknowledging safety challenges in the TRAVERSE trial. Management anticipates minimal competitive impact due to the logistical advantages of their five-minute infusion profile over existing high-toxicity therapies.
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
Allogene Therapeutics (ALLO) reported a narrower-than-expected Q2 2026 loss of 13 cents per share, beating the Zacks Consensus Estimate of 16 cents, primarily due to lower research and development costs. The company's cash position extended its runway into 2029, and it is progressing with its lead pipeline drug cema-cel in the ALPHA3 study and ALLO-329 for autoimmune diseases, with data updates expected later in 2026 and 2027.
Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says
RBC Capital Markets reiterated that Allogene Therapeutics remains an attractive investment due to its appealing valuation and distinctive clinical strategy. The company highlighted a 41% improvement in minimal residual disease on the large B-cell lymphoma front. Access to the full analysis requires a premium subscription.
Allogene Therapeutics, Inc. Announces Cemacabtagene Ansegedleucel (Cema-Cel) Is Being Evaluated in Alpha3, the First Pivotal, Randomized Phase 2 Trial in LBCL
Allogene Therapeutics announced that cemacabtagene ansegedleucel (cema-cel) is being evaluated in ALPHA3, a pivotal Phase 2 trial for high-risk Large B-Cell Lymphoma (LBCL) patients. The trial aims to assess if MRD-guided treatment can delay or prevent relapse, with early data showing favorable MRD negativity rates and a well-tolerated safety profile for cema-cel. The company also provided an update on its ALLO-329 program for autoimmune diseases, which continues enrollment in its Phase 1 RESOLUTION trial.
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
Allogene Therapeutics (ALLO) reported a narrower-than-expected loss of 13 cents per share in Q2 2026, surpassing the Zacks Consensus Estimate of 16 cents, primarily due to reduced research and development costs. The company's cash position extended its runway into 2029, and it is making significant progress in its ALPHA3 study for cema-cel and its RESOLUTION study for ALLO-329 in autoimmune diseases.
722,928 Shares in Allogene Therapeutics, Inc. $ALLO Acquired by Hennion & Walsh Asset Management Inc.
Hennion & Walsh Asset Management Inc. has acquired a new position of 722,928 shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO), valued at approximately $1.5 million. This purchase gives the firm a 0.21% stake in the company, contributing to the 83.63% institutional ownership of Allogene. The acquisition comes as Allogene's cema-cel program received FDA RMAT and Fast Track designations, and the company reported a smaller-than-expected second-quarter loss of $0.13 per share.
Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast
Allogene Therapeutics reported a narrower-than-expected loss for Q2 2026, with adjusted EPS of negative $0.13 against a forecast of negative $0.17. Revenue significantly surpassed expectations, driven primarily by clinical advancements rather than financial metrics. The company's ALPHA3 trial in large B-cell lymphoma is progressing well, with regulatory designations strengthening its position, and the stock saw an after-hours increase following the mixed market reaction during regular trading.
Allogene Therapeutics earnings beat by $0.04, revenue topped estimates
Allogene Therapeutics (NASDAQ: ALLO) reported better-than-expected earnings for the second quarter, beating analyst EPS estimates by $0.04 and significantly exceeding revenue forecasts. The company posted an EPS of $-0.130 on revenue of $4.64M. The stock has shown strong performance, rising 2.750% in the last three months and 97.600% over the past year.
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported its second-quarter 2026 financial results, highlighting significant progress in its clinical trials for cancer and autoimmune diseases. The company's cema-cel program received RMAT and Fast Track designations from the FDA, and its ALPHA3 trial is accelerating site activations ahead of schedule. Allogene ended the quarter with $423.6 million in cash, projecting a runway into 2029.
Allogene Therapeutics: Q2 Earnings Snapshot
Allogene Therapeutics Inc. reported a Q2 loss of $42.7 million, or 13 cents per share, surpassing Wall Street expectations which had forecast a loss of 16 cents per share. The immuno-oncology company generated $4.5 million in revenue for the period. Shares of Allogene Therapeutics were trading at $2.08 on Wednesday, double their value from a year ago.
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported its second-quarter 2026 financial results, highlighting significant progress in its ALPHA3 program for cema-cel in 1L Large B-cell Lymphoma, which received RMAT and Fast Track designations from the FDA. The company also provided an update on its Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease, with clinical data expected in Q4 2026. Allogene ended the quarter with $423.6 million in cash, projecting a cash runway into 2029.
Allogene Therapeutics, Inc. expected to post a loss of 17 cents a share - Earnings Preview
Allogene Therapeutics, Inc. is projected to report a loss of 17 cents per share. This information comes from an earnings preview, indicating an anticipated financial performance for the company. The full article provides more details, accessible through a TradingView subscription.
State Street Corporation (ALLO) discloses 5.5% beneficial stake in Allogene
State Street Corporation has disclosed a 5.5% beneficial ownership stake in Allogene Therapeutics, Inc., holding 19,025,826 shares of common stock. The filing, a Schedule 13G, indicates that State Street exercises shared voting power over 18,772,433 shares and shared dispositive power over all 19,025,826 shares, with no sole voting or dispositive power. Several State Street subsidiaries, including SSGA Funds Management, Inc., are involved in these holdings.
Allogene Therapeutics (ALLO) stake: Belldegrun group reports 3.9% ownership
Dr. Arie Belldegrun and affiliated entities have filed an amended passive ownership report for Allogene Therapeutics (ALLO), disclosing a beneficial ownership of 13,610,578 shares, which represents 3.9% of the outstanding common stock as of May 11, 2026. This total includes shares from stock options and holdings through Bellco Legacy and Vida Ventures. The filing confirms that each reporting person now owns 5% or less of Allogene's outstanding common stock.
Allogene Therapeutics Q2 Results: Earnings Call Set for Aug 12
Allogene Therapeutics will report its Q2 2026 financial results and provide a business update on August 12, 2026, after market close, followed by a webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. The company, a clinical-stage biotechnology firm, focuses on developing allogeneic CAR T products for cancer and autoimmune diseases, aiming to make cell therapy more accessible. Investors can register for the call to participate or access a listen-only webcast and its replay on the company's website.
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
Allogene Therapeutics announced it will report its second quarter 2026 financial results and provide a business update on August 12, 2026, after market close. This will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. The company, a clinical-stage biotechnology firm, specializes in developing allogeneic CAR T products for cancer and autoimmune diseases.
Allogene sets Aug. 12 update on cancer and autoimmune disease
Allogene Therapeutics (NASDAQ: ALLO) announced it will report its second-quarter 2026 financial results and provide a business update on August 12, 2026, after the market close. The company will host a live audio webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET, accessible via its investor relations website. Allogene specializes in developing allogeneic CAR T (AlloCAR T) products for cancer and autoimmune diseases.
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
Allogene Therapeutics, Inc. will report its second quarter 2026 financial results and provide a business update on August 12, 2026, after market close. A live audio webcast and conference call will follow at 2:00 p.m. PT/5:00 p.m. ET. The company, a clinical-stage biotechnology firm, specializes in developing allogeneic CAR T products for cancer and autoimmune diseases.
Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA RMAT, Fast Track Designations
Allogene Therapeutics announced that its drug, Cemacabtagene Ansegedleucel, received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration. This article from MT Newswires discusses the regulatory approvals for the company's treatment. However, the full details of the article require a premium subscription.
Insider Sellers Might Regret Selling Allogene Therapeutics Shares at a Lower Price Than Current Market Value
Insiders at Allogene Therapeutics, Inc. sold US$603k worth of stock over the past year at an average price of US$1.85, which is higher than the current share price of US$1.66. While a recent major sale by Co-Founder David Chang was near the current price, the overall trend suggests insiders might regret selling at lower prices. The company has modest insider ownership of 4.3% (US$26m), and no insider purchases have occurred in the last year, suggesting insiders might have missed out on potential gains.
Allogene Therapeutics Inc (ALLO) Risk Assessment: Volatility, Financial Risk & Investment Risk
Allogene Therapeutics Inc (ALLO) has a current risk assessment score of 3.70, placing it 115th out of 384 companies in the Biotechnology & Medical Research industry. The company's beta value of 0.47 indicates lower volatility compared to the S&P 500. The report details various risk metrics including VaR, maximum drawdown, volatility, and Sharpe Ratios over different timeframes.
Allogene Therapeutics stock rises on FDA regulatory designations
Allogene Therapeutics Inc. (NASDAQ:ALLO) shares increased after the FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to its experimental therapy cema-cel. These designations are for treating adult patients with large B-cell lymphoma (LBCL) who test positive for minimal residual disease (MRD) after first-line therapy. The regulatory statuses enable more frequent FDA engagement for an efficient development and review process, based on positive interim analysis data from the ALPHA3 trial.
Allogene Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy And Fast Track Designations For Cemacabtagene Ansegedleucel As First-Line Consolidation Therapy For Large B-Cell Lymphoma
Allogene Therapeutics has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA for its investigational CAR T product, cemacabtagene ansegedleucel (cema-cel). These designations are for cema-cel as a first-line consolidation therapy for adult patients with high-risk large B-cell lymphoma (LBCL) who show positive results for minimal residual disease (MRD) after initial therapy. The decision was based on promising interim analysis from the ALPHA3 trial, which demonstrated a significant increase in MRD negativity in the cema-cel arm compared to the observation arm, with a favorable safety profile.
Allogene Reports No Minimal Residual Disease in 7 of 12 Cema-Cel Patients
Allogene Therapeutics announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to its investigational allogeneic CAR T therapy cemacabtagene ansegedleucel (cema-cel). These designations are based on interim data from the pivotal ALPHA3 trial, where 58.3% of cema-cel-treated patients achieved MRD negativity by Day 45, significantly outperforming the observation arm. The therapy also demonstrated a favorable safety profile, and these regulatory recognitions are expected to expedite its development and review process for adult large B-cell lymphoma patients who are MRD-positive after initial chemoimmunotherapy.
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
Allogene Therapeutics has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA for its investigational allogeneic CAR T product, cemacabtagene ansegedleucel (cema-cel). These designations are for cema-cel's use as a first-line consolidation therapy for adult patients with high-risk large B-cell lymphoma (LBCL) who test positive for minimal residual disease (MRD) after initial treatment. The decision is based on promising interim futility analysis from the ALPHA3 trial, which showed rapid and substantial MRD reduction and good tolerability, highlighting cema-cel's potential to transform LBCL treatment.
